Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
To put that into more concrete terms: on the 0 to 18 CDR-SB scale, lecanemab, a monoclonal antibody thats not approved on the NHS (because of cost) but is approved by the FDA, showed a 0.45-point advantage at 18 months, which is about 27% slower than placebo
This gives foreign sponsors confidence that trials conducted in Korea wont face regulatory snags
Is there a safer alternative to aspirin for headaches while on this medication
Nayan Patel: right
US$ 29.01
US$ 28.06
US$ 20.30
US$ 28.24
US$ 27.75
